Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	55.27B
Revenue (ttm)	13.62B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	1.13
PE Ratio	27.59
Forward PE	27.03
Dividend	0.22 (0.98%)
Ex-Dividend Date	Jul 4, 2025

Volume	11,270,171
Average Volume	21,675,687
Open	22.34
Previous Close	22.50
Day's Range	22.06 - 22.64
52-Week Range	8.06 - 26.45
Beta	0.93
RSI	58.95
Earnings Date	Aug 22, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY